Properties and medical use of flavonolignans (Silymarin) from Silybum marianum

Phytotherapy Research

Volumn 10, Issue SUPPL. 1, 1996, Pages

  Leng Peschlow, Elke ^a  

^a Madaus AG   (Germany)

Author keywords

antifibrotic; antioxidant; liver therapy; silymarin

Indexed keywords

ALCOHOL; ENVIRONMENTAL POISON; FLAVONOID; ISOSILIBININ; LEUKOTRIENE; LIGNAN; PLANT EXTRACT; SILIBININ; SILICRISTIN; SILIDIANIN; SILYBUM MARIANUM EXTRACT; SILYMARIN; UNCLASSIFIED DRUG;

AMANITA PHALLOIDES; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BOTANY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG MIXTURE; DRUG USE; FRUIT; HUMAN; ISOMER; LIPID PEROXIDATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MEMBRANE DAMAGE; MUSHROOM POISONING; NONHUMAN; PROTEIN SYNTHESIS;

AMANITA PHALLOIDES; ANIMALIA; BASIDIOMYCOTA; CARDUUS; CIRSIUM; SILYBUM MARIANUM;

EID: 0030512154     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Albrecht, M., Frerick, H., Kuhn, U. and Strenge-Hesse, A. (1992). Die Therapie toxischer Leberschäden mit Legalon®. Z. Klin. Med. 47, 87-92.
2. Boari, C., Montanari, F. M., Galletti, G. R, Rizzoli, D., Baldi, E., Caudavella, R. and Gennari, P. (1981). Therapeutische Wirkungen von Silymarin bei berufsbedingten toxischen Hepatopathien. In, Der Toxisch-metabolische Leberschaden, ed by De Ritis et al., pp. 46-53. Hansisches Verfagskontor, Lübeck.
3. Dehmlow, C., Erhard, J. and de Groot, H. (1996). Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23, 749-754.
4. Feher, J., Deak, G., Müzes, G., Istvan, L., Vilmos, N., Kristof, N. and Mihaly, K. (1989). Silymarin kezelés májvédö hatása idült alkoholos májbetegsegben. Orvosi Hetilap (Medical Weekly) 130, 2723-2727.
5. Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Benda, L., Lochs, H., Meryn, S., Base, W. and Schneider, B. (1989). Randomized controlled trial of Silymarin treatment in patients with cirrhosis of the liver. J. Hepatol. 9, 105-113.
6. Fuchs, E. C., Gressner, A. M., Weyhem Meyer, R. and Weiner, O. H. (1995). Identification of the antifibrogenic properties of silibinin: effect on TGF-β and matrix gene expression of hepatic stellate cells. Hepatology 22, 286 A.
7. Grüngreiff, K., Albrecht, M. and Strenge-Hesse, A. (1995). Nutzen der medikamentösen Lebertherapie in der hausärztlichen Praxis. Die Medizinische Welt 46, 222-227.
8. Leng-Peschfow, E. and Strenge-Hesse, A. (1991). Die mariendistel (Silybum marianum) und Silymarin als Lebertherapeutikum. Z. Phytotherapie 12, 162-174.
9. Saba, P., Galeone, F., Salvadorini, F., Guarguaglini, M. and Troyer, C. (1976). Therapeutische Wirkung von Silymarin bei durch Psychopharmaka verursachten chronischen Hepatopathien. Gazz. Med. Ital. 135, 236-251.
10. Salmi, H. and Sarna, S. (1982). Effect of silymarin on chemical, functional, and morphological alterations of the liver. Scand. J. Gastroenterol. 17, 517-521.
11. Schuppan, D., Lang, T., Gerling, G., Leng-Peschlow, E., Krumbiegel. G., Riecken, E. O. and Waldschmidt, J. (1995). Antifibrotic effect of silymarin in rat secondary biliary fibrosis induced by duct obliteration with ethibloc. Z. Gastroenterol. 32, 45-46.
12. Szilard, S., Szentgyoergyi, D. and Demeter, I. (1988). Protective effect of LEGALON in workers exposed to organic solvents. Acts Medica Hungarica 45, 249-256.
13. Velussi, M., Cernigoi, A. M., Viezzoli, L., Dapas, F., Caffau, C, and Zilli, M. (1993). Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Curr. Ther. Res. 53, 533-545.